Project Grant HT94252510444
Award Date
9/30/25
Completion Date
9/29/29
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Bloomington, IN 47405, USA
Similar Awards
This federal Project Grant award of $1,305,270.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "OVARIAN CANCER ACADEMY: ADVANCING OVARIAN CANCER RESEARCH THROUGH MENTORSHIP, NETWORKING, AND COLLABORATIONS" initiative. The award, with a performance period from September 30, 2025 to September 29, 2029, will be administered by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the...
The Trustees of Indiana University received a $950,999 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2021 through May 2025 to target EZH2-HOTAIR in order to block platinum-induced ovarian cancer stem cell enrichment and reduce recurrence. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,188,750.00 to the Trustees of Indiana University (Indiana University) for the project "ANCESTRY-DEPENDENT STROMAL CELL FACTORS IN BREAST CANCER PROGRESSION." The award period runs from January 31, 2025 to January 30, 2028. This research grant supports advanced biomedical investigations aimed at transforming healthcare for military service...
The Trustees of Indiana University were awarded a $956,104 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from May 2022 to May 2026 to decipher the role of progesterone in ovarian cancer risk for BRCA mutation carriers. Through this award, Indiana University researchers will investigate medical solutions for the battlefield and transform health care for service members and the...
The federal Project Grant award of $480,000.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research by Northwestern University to investigate the role of translation heterogeneity in ovarian cancer. The research aims to uncover insights that can transform healthcare for military service members, veterans, and the broader public. The project has a performance period from September 1, 2024 to August 31, 2026. This award is...
This federal Project Grant award for $1,178,136.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the University of Pennsylvania to exploit the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The award has a performance period from April 15, 2025 to April 19, 2029 and aims to transform healthcare for military service members, veterans, and the broader...
This Project Grant award, valued at $750,000.00, was issued on May 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the University of Houston System to investigate "Circulating Immune Complexes as Biomarkers for Early Detection and Monitoring of Ovarian Cancer." The research aims to transform healthcare for military service members, veterans, and the broader public through innovative...
This $1,323,505 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to explore immune-tumor cell metabolic interactions in prostate cancer among African American men. The grant recipient, Trustees of Indiana University, will leverage its expertise in biomedical sciences and public health to conduct this innovative research initiative. The award has a performance period from August 1, 2024 to July 31, 2027....
The Trustees of Indiana University were awarded a $3,930,678 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2022 to June 30, 2024 to target replication stress in pediatric and young adult osteosarcoma. The Military Medical Research and Development program supports biomedical research to transform military and public health care through innovative solutions. This award...
The Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), has been awarded a $1,576,423 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This federal grant, awarded on August 1, 2024, will support research to mitigate therapy resistance by combining CDK4/6 and PI3K/mTOR inhibition in pediatric and adolescent/young adult (AYA) osteosarcoma. The research project aims to develop...